Ivermectin Studies, Journals, Citations update
the chairman of the tokyo medical association Dr Haruo Ozaki recommends Ivermectin for use with covid patients. He notes that the parts of Africa that use Ivermectin to control parasites have a Covid death rate of just 2.2 per 100,000 as compared to 13 times that death rate among African countries that don’t use ivermectin
Even if you overdose on ivermectin the list of short term potential side effects are not severe. They include: numbness, tingling difficulty maintaining balance, jaundice. The most common side effects are abdominal pain, diarrhea, fatigue, nasea, dizziness. Ivermectin has been in use for 40 years, won nobel prize in 2015 for its anti-parasitic properties,
Gold Standard Scientific Trial criteria
- prospective study
- double blind
- randomized with a treatment and control group
- should be well-matched in as many variables as possible.
It is true that 4 of the 23 ivermectin studies were later retracted due to not meeting this gold-standard but this exhibits bias in-itself by holding ivermectin to a higher standard than the vaccine, which still has yet to meet 3 of the 4 standard criteria namely
- Elderly and those with severe allergies were not used in any of the control groups
- Comirnaty is still in the first year of two year trial period. The study was double-blind for just the initial two weeks – since then all but 7% of the placebo group have been inoculated.
As of early 2021 there were 47 trials undergoing listed at clinicaltrials.gov 14 of which have been completed.
read more about ivermectin on this site : Ivermectin Powerful Antiviral Ivermectin Effective with better Safety Record than Pfizer, Moderna Vaccines
- Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
Dhaka medical college Bangladesh October 9, 2020 randomized double blind trial
study began with 400 cases of mild covid
– half received standard treatment
– half received doxycycline + 6mg ivermectin per day.
results treatment group: 61% had early recovery, 23% late recovery, 9% severe outcome
placebo: 44% early recovery, 38% recovery, 18% severe outcome results : ivermectin = better outcome
randomized sequential assignment study with no masking at Zagazig University, Egypt
Study completed in August, reported in October 2020
223 of which received prophylactic ivermectin dosed based on weight.
7.4% of the treatment group vs 58.4% of the control group developed symptoms of Covid-19
3. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID 19
Eurnekien public hospital, Argentina, October 2020
- 131 standard care ivermectin on the mucosa + standard treatment
- 98 received no ivermectin
- everyone is followed for 1 month.
noone in the ivermectin group tested positive for covid. 11% of the standard prophylactic group tested positive.
using 200ug/kg ivermectin and doxycyline together
reduced mean time of recovery from 17 days to 9 days
Benha University, Egypt concluded December 28, 2020
400 symptomatic + 200 healthcare contacts.
4 groups – one of which used Ivermectin 400ug/kg
concluded that Ivermectin was much more effective than hydroxychloroquine specifically mean hospital stay reduced from 18+/- 8 days to 5+/-1 day.
there was no placebo arm (noone in the study received no treatment) however the 1 group which received ivermectin did significantly better than the other groups which took different treatments.
retrospective observational study conducted looking at patients with hospitalized covid dated October 12, 2020
involves 4 different hospitals in Florda
173 treated with 200ug/kg ivermectin dose
107 treated without plaquenil, azithromyacin but also no ivermectin
concluded risk reduction of 11% but no difference in median length of hospital stay. overall mortality rate 15% vs 25% control group. The mortality rate involving severe cases with pulmonary involvement was 38% vs 80.7% in the non ivermectin group.
500 people enrolled in two groups half and half.
ivermectin based on weight vs placebo
% requiring hospitalization, number of days in the hospital, time to hospital, percent that needs urgent care. still in trial – results look promising.
Limitations: Low percentage of hospitalization events, dose of ivermectin and not including only high-risk population.
Conclusion: Ivermectin had no significant effect on preventing hospitalization of patients with COVID-19. Patients who received ivermectin required invasive MVS earlier in their treatment. No significant differences were observed in any of the other secondary outcomes.
January 14, 2021 NIH’s COVID-19 Treatment Guidelines Panel upgraded its position on Ivermectin to : “As such, the Panel has determined that there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19.”
August 27, 2020 : The COVID-19 Treatment Guidelines Panel recommends against the use of ivermectin for the treatment of COVID-19, except in a clinical trial” stated then the NIH Panel, arguing that the “available clinical data on the use of ivermectin to treat COVID-19 are limited.”https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ivermectin/
NIH details on January 14 regarding neutral tone : “Since the last revision of the Ivermectin section of the Guidelines, results from several randomized clinical trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or made available as non-peer-reviewed manuscripts. Updates to the Ivermectin section that are underway will include discussion of these studies. Because many of these studies had significant methodological limitations and incomplete information, the Panel cannot draw definitive conclusions about the clinical efficacy of ivermectin for the treatment of COVID-19.”
NIH concludes from its current analysis that, “results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide further guidance on the role of ivermectin in the treatment of COVID-19.”
Both of these recommendations were made before or during most of these trials. The August recommendation-against-use did allow for use in clinical studies – which it eventually was. Many of those studies reported positive results.